Inverse associations of HDL cholesterol and oxidized HDL with d-dimer in patients with type 2 diabetes mellitus

Ebara, Sohei; Marumo, Mikio; Yamabata, Chika; Nishibe, Ikumi; Soneda, J; Mukai, Jun; Ohki, Makoto; Uchida, Kagehiro; Wakabayashi, Ichiro

doi:10.1016/j.thromres.2017.04.018

Cited by 12 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study of risk and prediction for T2DM patients with or without nephropathy, the results demonstrated that there were decreased aPTT and PLT and increased D-D levels in T2DM patients without complications compared with controls, which indicated that diabetics had decreased level of PLT count and relatively shortened aPTT as well as elevated D-D level. And other reports seem to partly prove the present results [ 22 , 23 ]. At the same time, increased FIB, PLT, and D-D as well as decreased FDR levels were found in patients with DN compared with those without complications.…”

Section: Discussionsupporting

confidence: 90%

Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy

Pan¹,

et al. 2018

Disease Markers

View full text Add to dashboard Cite

It would be important to predict type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN). This study was aimed at evaluating the predicting significance of hemostatic parameters for T2DM and DN. Plasma coagulation and hematologic parameters before treatment were measured in 297 T2DM patients. The risk factors and their predicting power were evaluated. T2DM patients without complications exhibited significantly different activated partial thromboplastin time (aPTT), platelet (PLT), and D-dimer (D-D) levels compared with controls (P < 0.01). Fibrinogen (FIB), PLT, and D-D increased in DN patients compared with those without complications (P < 0.001). Both aPTT and PLT were the independent risk factors for T2DM (OR: 1.320 and 1.211, P < 0.01, resp.), and FIB and PLT were the independent risk factors for DN (OR: 1.611 and 1.194, P < 0.01, resp.). The area under ROC curve (AUC) of aPTT and PLT was 0.592 and 0.647, respectively, with low sensitivity in predicting T2DM. AUC of FIB was 0.874 with high sensitivity (85%) and specificity (76%) for DN, and that of PLT was 0.564, with sensitivity (60%) and specificity (89%) based on the cutoff values of 3.15 g/L and 245 × 109/L, respectively. This study suggests that hemostatic parameters have a low predicting value for T2DM, whereas fibrinogen is a powerful predictor for DN.

show abstract

Section: Discussionsupporting

confidence: 90%

Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy

Pan¹,

et al. 2018

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Recent studies indicated that plasma Endothelin-1 (ET-1) and D-dimer levels were potential biomarkers of the no-reflow phenomenon or prognosis of STEAMI patients post PCI [ 7 – 9 ]. It is well known that the vascular pathology is common in type 2 diabetes mellitus (T2DM) patients [ 10 – 12 ]. Previous studies have shown that the T2DM condition can enhance the basal level of plasma ET-1 and D-dimer [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

The Value of Combining Plasma D-Dimer and Endothelin-1 Levels to Predict No-Reflow After Percutaneous Coronary Intervention of ST-Segment Elevation in Acute Myocardial Infarction Patients with a Type 2 Diabetes Mellitus History

et al. 2018

View full text Add to dashboard Cite

BackgroundNo-reflow phenomenon is a well-known problem, often accompanying percutaneous coronary intervention (PCI) for ST-segment elevation acute myocardial infarction (STEAMI). This study investigated the value of plasma D-dimer and Endothelin-1 (ET-1) levels on admission in predicting no-reflow after primary PCI and long-term prognosis in STEAMI patients with type 2 diabetes mellitus (T2DM).Material/MethodsThere were 822 patients with STEAMI and T2DM undergoing successful primary PCI included in this study: 418 patients showed normal re-flow after PCI, while 404 patients showed no-reflow phenomenon after PCI. The predictive value of plasma ET-1 and D-dimer level, and other clinical parameters for the no-reflow phenomenon were analyzed.ResultsThe high plasma ET-1 and D-dimer levels showed predictive value for the no-reflow phenomenon in STEAMI patients with T2DM. Patients with high D-dimer and ET-1 levels showed higher risk (4.212, with 95%CI of 2.973–5.967 and 2.447 with 95%CI of 1.723–3.476, respectively) of no-reflow phenomenon compared with patients with low plasma D-dimer and ET-1 levels. Sensitivity of high plasma ET-1 and D-dimer levels in predicting no-reflow was 0.766. Both plasma D-dimer and ET-1 were adverse prognosticators for STEAMI patients with a T2DM post PCI (P<0.001).ConclusionsIn conclusion, plasma D-dimer and ET-1 levels on admission independently predict no-reflow after PCI in STEAMI patients with T2DM. When combined, the D-dimer and ET-1 levels as predictive and prognostic values are clinically promising. The plasma D-dimer and ET-1 levels provided a novel marker for treatment selection for the STEAIM patients with a T2DM history.

show abstract

“…A previous study showed that D-dimer can stimulate monocytes in vitro to release inflammatory cytokines (such as IL-1β and IL-6), which indicates that D-dimer may facilitate localized coagulation ( 46 ). Moreover, increased plasma D-dimer was also found to be independently associated with an inflammatory state (assessed by IL-6) and dyslipidemia in T2D ( 39 , 40 ), which could contribute to nerve dysfunction and neuropathy. Furthermore, increased plasma D-dimer was also a marker of psychosocial distress ( 47 , 48 ), which has been shown to participate in the maladaptations of the peripheral and central nervous systems ( 49 , 50 ).…”

Section: Discussionmentioning

confidence: 95%

“…When compared to the healthy controls, the level of plasma D-dimer was obviously elevated in the first-degree relatives of T2D ( 35 ), prediabetes ( 18 ), gestational hypertension ( 36 ), polycystic ovary syndrome ( 37 ), and metabolic syndrome ( 38 ), let alone in overt T2D. Moreover, plasma D-dimer was observed to be independently associated with inflammatory cytokines ( 39 ), oxidized LDL ( 40 ), poor glycemic control (hyperglycemia, glycemic variability, and hypoglycemia) ( 41 – 43 ), diabetic retinopathy and nephropathy ( 14 , 15 ), and CVD ( 17 ) in patients with T2D. In addition, plasma D-dimer levels were also increased in parallel with the differential stages from family history of diabetes to prediabetes to T2D with CVD complications ( 18 ), which suggested that plasma D-dimer could be applied to indicate the progressive nature of diabetes and diabetes-related complications.…”

Section: Discussionmentioning

confidence: 99%

Increased plasma D-dimer levels may be a promising indicator for diabetic peripheral neuropathy in type 2 diabetes

Zhuang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundIncreased plasma D-dimer levels have been reported to be associated with a range of adverse health outcomes. This study aimed to determine whether plasma D-dimer is connected to diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes (T2D).MethodsThis study was part of a series exploring the potential risks for DPN. All patients were questioned for neurologic symptoms, examined for neurologic signs, and received nerve conduction studies to collect nerve action potential onset latency, amplitude, and nerve conduction velocity (NCV). Composite Z scores of latency, amplitude, and NCV were calculated. DPN was confirmed as both at least a neurologic symptom/sign and an abnormality of nerve conduction studies. Coagulation function indices, such as plasma D-dimer levels, were also synchronously detected.ResultsWe finally recruited 393 eligible patients for this study, of whom 24.7% (n = 97) were determined to have DPN. The plasma D-dimer level was found to be closely associated with the composite Z score of latency, amplitude, and NCV after adjusting for other coagulation function indices and clinical covariates (latency: β = 0.134, t = 2.299, p = 0.022; amplitude: β = –0.138, t = –2.286, p = 0.023; NCV: β = –0.139, t = –2.433, p = 0.016). Moreover, the prevalence of DPN in the first, second, third, and fourth quartiles (Q1, Q2, Q3, and Q4) of the D-dimer level was 15.2%, 15.9%, 26.4%, and 42.7%, respectively (p for trend < 0.001). The corresponding adjusted odds ratios and 95% CIs for DPN in D-dimer quartiles were 1, 0.79 (0.21–2.99), 1.75 (0.49–6.26), and 5.17 (1.38–19.42), respectively. Furthermore, the optimal cutoff value of the plasma D-dimer level to discriminate DPN was ≥0.22 mg/L (sensitivity = 67.01%, specificity = 58.78%, and Youden index = 0.26) after analysis by the receiver operating characteristic curve.ConclusionsIncreased plasma D-dimer levels may be a promising indicator for DPN in patients with T2D.

show abstract

Inverse associations of HDL cholesterol and oxidized HDL with d-dimer in patients with type 2 diabetes mellitus

Cited by 12 publications

References 9 publications

Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy

Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy

The Value of Combining Plasma D-Dimer and Endothelin-1 Levels to Predict No-Reflow After Percutaneous Coronary Intervention of ST-Segment Elevation in Acute Myocardial Infarction Patients with a Type 2 Diabetes Mellitus History

Increased plasma D-dimer levels may be a promising indicator for diabetic peripheral neuropathy in type 2 diabetes

Contact Info

Product

Resources

About